| Trial ID: | L2930 |
| Source ID: | NCT00143104
|
| Associated Drug: |
Inhaled Insulin
|
| Title: |
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: Inhaled insulin
|
| Outcome Measures: |
Primary: To assess in patients with type 1 diabetes mellitus the effects, if any, on lung lining, fluid cell count and differential within subjects after 12 weeks of inhaled insulin therapy compared to 12 weeks of subcutaneous short-acting therapy. | Secondary: (1) Albumin and fibrinogen concentrations, and airway appearance in the above subjects. (2) routine safety, tolerance, and efficacy in the above subjects.
|
| Sponsor/Collaborators: |
Sponsor: Pfizer | Collaborators: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2004-12
|
| Completion Date: |
2006-10
|
| Results First Posted: |
|
| Last Update Posted: |
2008-03-11
|
| Locations: |
Pfizer Investigational Site, Glendale, Arizona, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, San Antonio, Texas, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00143104
|
